All In Biotech

Drug Trial Radar · NCT04203485

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

A Randomized, Open-Label, Controlled, Multicenter Phase III Study of Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone Versus Platinum-based Chemotherapy for First-line Treatment in Subjects With PD-L1 Positive Relapsed or Advanced NSCLC

Last checked: Nov 19, 2026Latest source record: May 8, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 762 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

762

Planned (sponsor's estimate)

Start

Jun 15, 2020

Primary completion

Mar 31, 2022

Study completion May 31, 2022

Sponsor

Sponsor type
Industry
First posted
Dec 18, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the efficacy and safety of Camrelizumab (200mg,q2w) combined with Apatinib(250mg qd) in subjects with PD-L1 positive relapsed or advanced non-small cell lung cancer.

Conditions

  • PD-L1 Positive Non-small Cell Lung Cancer

Interventions

  • Camrelizumab 200mgBiological

    Camrelizumab 200mg q2w ivgtt

  • Apatinib Mesylate 250mgDrug

    Apatinib Mesylate 250mg po qd

  • Pemetrexed disodium for injectionDrug

    Pemetrexed disodium for injection 500 mg/m2 q3w

  • Paclitaxel injectionDrug

    Paclitaxel injection 175 mg/m2 q3w

  • CarboplatinDrug

    Carboplatin AUC 5 mg/mL/min q3w

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) assessed by Independent review committee (IRC)Time frame: up to 2 years
  2. Overall survivalTime frame: up to 2 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.